Previous 10 | Next 10 |
CNS Pharmaceuticals ( CNSP ) has filed a preliminary prospectus for a 2.125M-share IPO at $4 -5 per share, valuing the offering at $9.6M from the midpoint. More news on: CNS Pharmaceuticals, Reata Pharmaceuticals, Inc., Healthcare stocks news, IPO News, Read more ...
The single biggest advantage a value investor has is not IQ. It's patience and waiting. Waiting for the right pitch, and waiting for many years for the right pitch. - Mohnish Pabrai Investment research can be boring for some sectors, yet in the bioscience space, the pace of change is astro...
IRVING, Texas, June 05, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to bardoxolone methyl (bardoxolone) for the treat...
IRVING, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s progress in developing bardoxolone methyl (bardoxolone) for the treatment of chronic kidne...
IRVING, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced the enrollment of the first patient in the Phase 3 FALCON trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant pol...
There is a potential development in the near horizon which could disrupt an entire industry. The industry that stands to be disrupted is the current treatment for ESRD (End-Stage Renal Disease) Dialysis. The potential development is a drug that might either delay or avoid ESRD coming from seve...
Reata Pharmaceuticals ( RETA ) is a late clinical stage biotechnology company with a chronic kidney disease therapy due to release results later this year. I last wrote about it in Reata Pharmaceuticals A Buy On Bardoxolone Data back in February 2018. The stock price then was $26.73 per sh...
Reata Pharmaceuticals, Inc. (RETA) Q1 2019 Results Earnings Conference Call May 09, 2019, 08:00 AM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup Adam ...
Reata Pharmaceuticals (NASDAQ: RETA ): Q1 GAAP EPS of -$0.98 beats by $0.02 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With Management Scheduled for Today, May 9, 2019 IRVING, Texas, May 09, 2019 (GLOBE NEWSWIRE) ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023